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Abstract
Recent research supports the beneficial effects of dietary polyunsaturated fatty acids 
(PUFAs) on inhibiting tumour development. Long‐chain fatty acids modulate the tumour 
cell response to chemotherapeutic drugs. Investigators recently claimed high dietary 
intake of omega‐6 polyunsaturated fatty acids such as linoleic acid especially in associa‐
tion with a low intake of omega‐3 polyunsaturated fatty acids such as docosahexaenoic 
acid to increase risks for cancers of the breast, colon and possibly prostate. In addition to 
these facts, a number of investigations have demonstrated that a modified fatty acid ana‐
logues are promising molecules in cancer prevention and have potential in the treatment 
of cancer. Although billions of dollars have been spent on research and development on 
anticancer drugs, the disease remains uncontrolled. It is expected that anticancer agents 
preferentially kill tumour cells without causing adverse effects on normal cells. But this is 
rarely achieved with the existing cancer therapy. Hence, polyunsaturated fatty acids have 
come under the category of nutraceuticals/functional foods; their exploration in the treat‐
ment of cancer may be considered as safe. This chapter describes the effects of long‐chain 
fatty acids and their analogues in cancer chemotherapy.
Keywords: fatty acids, cancer, PUFA, fatty acid synthase, omega‐3
1. Introduction to fatty acids
Plants, animals and microbes generally contain even number of carbon atoms in straight 
chains, with a carboxylic group at one end and double bonds with cis configuration on the 
another end. The chain length of the common fatty acids varies between 14 and 22, but on 
occasions can span between 2 and 36 or even more in animal tissues. Fatty acids found in ani‐
mal tissues have one to six double bonds, whereas those in algae have up to five bonds. Higher 
plants rarely have more than three, whereas microbial fatty acids occasionally have more than 
one. The fatty acids, which are derived from triglycerides or phospholipids, have a chain of 
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4–28 carbons. Fatty acids, which are not attached to other molecules, are known as free fatty 
acids which on breakdown yield large quantities of ATP. Many cell types use either glucose 
or fatty acids for this purpose. In particular, heart and skeletal muscle prefer fatty acids [1].
Fatty acids may be monounsaturated, polyunsaturated or saturated (Figure 1). They help in 
moving oxygen through the blood stream to all parts of the body, aid cell membrane develop‐
ment and strengthen the organs and tissue. They also help in healthy skin and prevent early 
ageing and more importantly help rid the arteries of cholesterol build‐up.
2. Types of fatty acids
2.1. Saturated fatty acids
 Saturated fatty acids are straight‐chain compounds with 14, 16 and 18 carbon atoms. The 
most abundant saturated fatty acids found in animal and plant tissues are esterified with 
odd‐ and even‐numbered homologues with 2–36 carbon atoms. A list of common saturated 
fatty acids together with their trivial names and shorthand designations is given in Table 1.
2.2. Monoenoic fatty acids
Monoenoic fatty acids are straight‐chain fatty acids containing 10–30 carbon atoms with one 
cis‐double bond. The double bond can be in different positions and this is specified in the 
systematic nomenclature in relation to the carboxyl group (Table 2).
2.3. Polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) are fatty acids which contain multiple double bonds and 
are subdivided into families according to their derivation from specific biosynthetic precur‐
sors. In each instance, the families contain between two and six cis‐double bonds separated 
Figure 1. Naturally occurring fatty acids.
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by single methylene\ groups, and have the same terminal structure [2]. A list of some of the 
important PUFAs is presented in Table 3.
2.4. Branched‐chain and cyclopropane fatty acids
Branched‐chain fatty acids, which occur widely in nature, are present as minor components 
except in bacteria, where they appear to replace unsaturated fatty acids functionally. The 
branch consists of a single methyl group, either on the penultimate (iso) or on the antepenul‐
timate (anteiso) carbon atoms [3, 4].
2.5. Oxygenated and cyclic fatty acids
A large number of hydroperoxy, hydroxyl and epoxy fatty acids (eicosanoids) are formed 
enzymatically as intermediates in the biosynthesis of prostanoids. A large number of hydroxy 
fatty acids occur in seed oils, and the best known of these is ricinoleic acid which is the prin‐
ciple constituent of castor oil. Polyhydroxy fatty acids are present in plant cutins, shellacs and 
many seed oils.
S. no. Systematic name Shorthand designation Trivial name
1. Ethanoic 2:0 Acetic
2. Butanoic 4:0 Butyric
3. Hexanoic 6:0 Caproic
4. Octanoic 8:0 Caprylic
5. Nonanoic 9:0 Pelargonic
6. Decanoic 10:0 Capric
7. Undecanoic 11:0 –
8. Dodecanoic 12:0 Lauric
9. Tridecanoic 13:0 –
10. Tetradecanoic 14:0 Myristic
11. Pentadecanoic 15:0 Myristic
12. Hexadecanoic 16:0 Palmitic
13. Heptadecanoic 17:0 Margaric
14. Octadecanoic 18:0 Stearic
15. Nonadecanoic 19:0 Margaric
16. Arachidic 20:0 Eicosanoic
17. Heneicosanoic 21:0 –
18. Docosanoic 22:0 Behenic
19. Tetracosanoic 24:0 Lignoceric
Table 1. Saturated fatty acids of general formula CH3(CH2)n COOH.
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2.6. Omega‐3 and omega‐6 fatty acids
The biological fatty acids are of different lengths, the last position is labelled as omega (ω). 
Omega‐3 fatty acids are long‐chain polyunsaturated fatty acids (18–22 carbon atoms) with the 
first of many double bonds beginning with the third carbon atom. However, omega‐6 fatty acids 
have the first of many double bonds beginning with the sixth carbon atom. Alpha‐linolenic acid 
(ALA) and linoleic acid (LA) are the parent compounds of the omega‐3 family and omega‐6 
family of fatty acids, respectively.
S. no. Systematic name Shorthand designation Trivial name
1. 9,12‐Octadecadienoic* 18:2(n‐6) Linoleic
2. 6,9,12‐Octadecatrienoic 18:3(n‐6) γ‐Linolenic
3. 8,11,14‐Eicosatrienoic 18:3(n‐6) Homo‐γ‐linolenic
4. 5,8,11,14‐Eicosatetraenoic 20:4(n‐6) Arachidonic
5. 4,7,10,13,16‐Eicosapentaenoic 20:5(n‐6) –
6. 9,12,15‐Octadecatrienoic 18:3(n‐6) α‐Linolenic
7. 5,8,11,14,17‐Eicosapentaenoic 20:5(n‐3) EPA
8. 7,10,13,16,19‐Docosapentaenoic 22:5(n‐3) –
9. 4,7,10,13,16,19‐Docosahexaenoic 22:5(n‐3) DHA
10. 5,8,11‐Eicosatrienoic 20:3(n‐9) Mead’s acid
*The double bond configuration in each instance is cis.
Table 3. Polyunsaturated fatty acids of general formula CH3 (CH2)m(CH=CHCH2)x(CH2) n COOH.
S. no. Systematic name Shorthand designation Trivial name
1. cis‐9‐Tetradecenoic 14:1(n‐5) Myristoleic
2. cis‐9‐Hexadecenoic 16:1(n‐7) Palmitoleic
3. trans‐3‐Hexadecenoic – –
cis‐6‐Octadecenoic 18:1(n‐12) Petraselenic
4. cis‐9‐Octadecenoic 18:1(n‐9) Oleic
5. cis‐11‐Octadecenoic 18:1(n‐7) cis‐Vaccenic
6. trans‐11‐Octadecenoic – Elaidic
7. cis‐9‐Eicosenoic 20:1(n‐11) Gadoleic
8. cis‐11‐Octadecenoic 18:1(n‐9) Gondic
9. cis‐13‐Docosenoic 22:1(n‐9) Erucic
10. cis‐15‐Tetracosenoic 24:1(n‐9) Nervonic
Table 2. Monoenoic fatty acids of general formula CH3(CH2)mCH=CH(CH2)nCOOH.
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Although the International panel of lipid experts says the ideal ratio of omega‐3 to omega‐6 
essential fatty acids is approximately 1:1, still we follow the ratio 20:1 in our diet [5]. Long‐
chain polyunsaturated fatty acids cannot be formed de novo but can be synthesized from the 
essential fatty acids like linoleic acid and alpha‐linolenic acid. These two essential fatty acids 
are desaturated and lengthened progressively by microsomal enzyme systems to form highly 
unsaturated, long‐chained fatty acids such as arachidonic acid and docosahexaenoic acid 
(DHA). The omega‐3 and omega‐6 fatty acids are not interconvertible. Dietary fish and fish oil 
supplements are a direct source of omega‐3 fatty acids and dietary oils have large quantity of 
omega‐6 fatty acids [6].
3. Polyunsaturated fatty acids as anticancer agents
Yonesawa and co‐workers carried out the inhibitory effect of conjugated eicosapentaenoic 
acid (cEPA) on mammalian DNA polymerase and topoisomerase activities and human cell 
proliferation. They found that the inhibitory effect of cEPA was stronger than that of the non‐
conjugated EPA and suggested the therapeutic potential of cEPA as a leading anticancer com‐
pound that poisons mammalian DNA polymerase (POLS) [7]. The work carried by Unduri 
revealed the tumouricidal and antiangiogenic actions of gamma‐linolenic acid (GLA) and its 
derivatives. It was found that GLA being an endogenous naturally occurring molecule had no 
significant side effects [8]. Paul et al. reported that the long‐chain eicosapentaenoic acid (EPA) 
and docosahexaenoic acids (DHA) have been consistently shown to inhibit the proliferation 
of breast and prostate cancer cell lines in vitro and to reduce the risk and progression of these 
tumours in animal experiments. Many investigations revealed that the above‐said fatty acids 
inhibit cyclooxygenase‐2 and the oxidative metabolism of arachidonic acid (AA) to PGE2. EPA and DHA also have been shown to inhibit lipoxygenase which metabolizes AA to hydroxyl 
eicosatetraenoic acids and leucotrienes which suppress apoptosis, stimulate angiogenesis 
and stimulate tumour cell division (Figure 2). Further, they explained that the n‐3 PUFAs 
potentially affect carcinogenesis by specific mechanisms [9]. These mechanisms are as fol‐
lows: (1) alteration of the response of immune system to cancer cells through the suppression 
of arachidonic acid (AA, 20:4n‐6)‐derived eicosanoid biosynthesis; (2) alteration of metabo‐
lism, cell growth and differentiation; (3) alteration of oestrogen metabolism, which leads to 
reduced oestrogen‐stimulated cell growth; (4) alteration of free radicals and productivity; 
and (5) alteration of the mechanisms involving insulin sensitivity and membrane fluidity. 
Interest in the use of supplementary omega‐3‐fatty acids to reduce the risk of cancer and other 
chronic‐debilitating conditions, including cardiovascular disease and cognitive impairment, 
stems from several long‐standing avenues of registration [9, 10]. Furthermore, the anticancer 
activity of fatty acids is well evidenced by Helmut et al. in experimental and human studies, 
which summarize that a high intake of omega‐3 PUFAs and monounsaturated fatty acids is 
protective in breast, colon and prostate cancers [11].
The author and her research group isolated methyl gamma linolenate (GLA‐ME) (1) from 
Spirulina platensis and the compound showed strong cytotoxicity against A‐549 cells [13] when 
compared with the standard drug Rutin. Rutin is a bioflavanol which is a well‐established 
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promising anticancer agent, and its mechanism may be due to the induction of apoptosis 
[14]. The comparative results are given in Figure 3 and Table 4, respectively. The probable 
mechanism may be due to the induction of apoptosis of tumour cells by augmenting free 
radical generation. It is evidenced by the research work carried out by Unduri et al. [8]. They 
also reported that the induction of apoptosis of tumour cells by GLA is due to its action at the 
gene/oncogene level and by altering BCl‐2 expression. Hence, it may be concluded that the 
cytotoxicity shown by GLA‐ME may be due to the induction of apoptosis effect. However, a 
detailed study of this mechanism is in progress.
Figure 2. Overview of the metabolism of n‐6 and n‐3 polyunsaturated fatty acids (PUFAs) into eicosanoids involved in 
inflammation and carcinogenesis [12].
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4. Polyunsaturated fatty acids as adjunct to chemotherapeutic agents
Kong and co‐workers found out that gamma linolenic acid modulates the response of multi‐
drug‐resistant K562 leukaemic cells to anticancer drugs. The study also revealed that GLA 
could modulate the response to anticancer drugs in P‐gp overexpressing multidrug‐resistant 
cells, which could be due to decrease P‐gp expression [15]. In another study, Julie and co‐
workers reported that alpha linolenic acid and docosahexaenoic acid alone combined with 
trastuzumab reduced HER2 overexpressing breast cancer cell growth but differentially regu‐
lated HER2‐signalling pathways. Their finding is different in classic mechanisms whereby n‐3 
PUFAs exert their effect in breast cancer. The results strongly suggest that DHA reduces 
growth factor receptor signalling as indicated by reductions in the phosphorylation of AKT 
and MAPK while the opposite effect is seen for the plant‐based n‐3 PUFA ALA [16]. Effenberger 
and co‐workers synthesized novel N‐acylhydrazones of doxorubicin which were derived 
from saturated, unsaturated and methyl or bornyl terminated fatty acids. The mode of cyto‐
toxic action of the hydrazones was largely apoptotic. They led to a distinct long‐term decrease 
Figure 3. In vitro cytotoxic studies □: GLA‐ME, Δ: standard rutin.
S. no. Compound Concentration (µM) % growth inhibition CTC
50
1. GLA‐;ME 3.333 97.45 0.468
2. 1.666 86.39
3. 0.833 72.38
4. 0.416 48.45
5. Rutin 3.333 98.65 0.442
6. 1.666 88.41
7. 0.833 75.25
8. 0.416 49.05
Table 4. Determination of cytotoxicity by SRB method.
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of bcl‐2 MRNA expression, the precise apoptotic mechanism and the involvement of caspases 
varied for the individual cell lines and test compounds. The apoptosis of 518A2 melanoma 
cells treated with some compounds was characterized by an early onset of initiator caspase‐9 
activity. By contrast, apoptosis elicited in 518A2 or in HL‐60 cells by remaining compounds 
was accompanied by high‐initiator caspase‐8 activity. The genuine slump of the bcl‐2 mRNA 
expression may be the reason for the observed quick and steep hike of the ratio of bax mRNA 
to bcl‐2 mRNA in 518A2 cells. Apoptosis induced by doxorubicin (2) and its derivatives (3) 
and (4) in HL‐60 and 518A2 cells also proceeds with a swift and distinct loss of mitochondrial 
membrane potential regardless of the divergent caspase kinetics. This was a proof that fatty 
acid analogues are more than just lipophilic shuttle groups [17].
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Piyali et al. studied the antiproliferative activity of somatostatin analogue with N‐terminal 
acylation with long‐chain fatty acids in human breast adenocarcinoma cell lines. The antiprolif‐
erative activity of the somatostatin analogue RC‐160 (D‐Phe‐Cys‐Tyr‐D‐Trp‐Lys‐Val‐Cys‐Trp‐
NH2) is limited by its short serum half‐life. To circumvent this limitation, fatty acids of chain lengths ranging from 4 to 18 were individually conjugated to the N‐terminal residue of RC‐160. 
Although the affinity of palmitoyl –RC‐160 towards somatostatin receptors remains unaltered 
when compared to the –RC‐160, it exhibited significantly higher antiproliferative activity on 
MCF‐7 cells. On further increase in the lipopeptide chain, the bioactivity of lipophilized –RC‐160 
was reduced. Increasing the peptide hydrophobicity beyond this range reduced the bioactivity 
of lipophilized –RC‐160. Accordingly, stearoyl –RC‐160 manifested lower antineoplastic activity 
and receptor‐binding affinity relative to palmitoyl –RC‐160 and RC‐160 itself. It was observed 
that an increase in bioactivity was manifested within an optimum range of the lipopeptide. The 
probable mechanisms may be alterations of the signalling pathways. Lipophilization of RC‐160 
with long‐chain fatty acids like palmitic acid improves its stability and antiproliferative activity, 
thereby improving the scope of enhancing its therapeutic index [18].
5. Fatty acid analogues as anticancer agents
A number of investigations have demonstrated that a variety of modified fatty acid analogues 
are promising molecules in cancer prevention and have potential in the treatment of cancer. 
Bhupender et al.synthesized fatty acyl amide derivatives of doxorubicin (5) and evaluated 
their in vitro anticancer activities. The results indicated that the designed molecule with com‐
parable antileukaemia activity to cytarabine with sustained release effect is possible by struc‐
ture modification [19].
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They also synthesized fatty acyl ester derivatives (6) of cytarabine and evaluated them for anti‐
leukaemia activity. Some of 2’,5’‐dimyristoyl derivatives of cytarabine were found to inhibit the 
growth of CCRF‐CEM cells [20]. Liu et al. reported the synthesis and antitumour evaluation of 
N4 fatty acyl amino derivatives of cytarabine. The bioavailability of cytarabine is low due to its 
low lipophilicity. In order to improve the lipophilicity and bioavailability of cytarabine, a series 
of fatty acyl amino acid cytarabine analogues (7) were synthesized. It was found that the deriv‐
atives synthesized were more lipophilic than cytarabine. The antitumour activity determined 
in HL‐600 and HeLa cells showed that the derivatives were more active in HeLa cells than 
cytarabine while most of them demonstrated similar activity to cytarbine in HL‐60 cells. The 
length of fatty acids in the derivatives seemed to have an impact on the activity observed [21].
Zhang Chun‐hong and co‐workers synthesized new panaxadiol fatty acid esters (8) and eval‐
uated them for their antitumour activity. Tumour cell used was Vero cell line. Positive con‐
trol was 5‐FU, blank was an RPMI1640 culture medium, negative control was an RPMI1640 
culture medium and the solvent for drugs to be tested. The compounds show the strongest 
antitumour activity [22].
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Earlier, the author of the present chapter has reported some novel fatty acid heterocyclic 
conjugates and their anticancer evaluation on human lung carcinoma cell lines [23, 24]. The 
compounds have shown comparable cytotoxicity towards human lung carcinoma cell lines. 
The compound (9), fatty acid chain substituted 1,3,4‐oxadiazole showed maximum cytotoxic 
activity. It was observed that the presence of toxophoric –N=C‐O‐ linkage in 1,3,4 oxadiazole 
nucleus may be responsible for the antitumour activity. Further, 1,3,4 oxadiazole is a good 
bioisostere of amide and ester functionalities with substantial improvement in biological 
activity in hydrogen‐bonding interactions with different targets responsible for the tumour 
development. The 1,2,4‐triazole substituted fatty acid analogues (10) displayed promising 
cytotoxicity towards human lung carcinoma cell lines. It was also observed that the length of 
the fatty acids plays a vital role in antitumour activity.
6. Fatty acid synthase as a potential target in cancer
Human fatty acid synthase (HFAS) is a multifunctional enzyme that is essential for the endog‐
enous synthesis of long‐chain fatty acid from its precursor acetyl Co‐A and malonyl Co‐A 
(Figure 4). Blocking HFAS activity causes cytotoxicity [25]. The unique carboxyl terminal 
thioesterase (TE) domain of fatty acid chain plays a critical role in regulating the chain length 
of fatty acid releases. Also, the up‐regulation of HFAS in a variety of cancer makes the thio‐
esterase domain a candidate target for therapeutic treatment [26]. It was evident from the 
literature that the long alkyl/alkenes tail of the fatty acids can bind into the long groove tunnel 
site of thio‐esterase domain of FAS which may be one of the factors of anticancer activities of 
fatty acids [27].
Employing these strategies, the author and her research group carried out the in silico stud‐
ies on fatty acid analogues. The group designed new derivatives of stearic acid and palmitic 
acid and studied their in silico‐binding affinities towards key enzyme human fatty acid syn‐
thase‐thio‐esterase domain (PDB code 2PX6). The literature clearly says that an identifica‐
tion of oncogenic antigen‐519 (OA‐519) from human breast carcinoma cells as FAS has made 
it an important diagnostic and prognostic marker for breast cancer patients [28, 29]. By 
superposing the scaffold structure of all our designed analogues, it is seen that these ana‐
logues bind in the same orientation and similar position in terms of the common structure, 
that is, long aliphatic chain (Figure 5). It complies with the fact that the substrate‐binding 
site of HFAS is made up of hydrophobic groove. The docking studies revealed that there 
are two hydrogen‐bonding interactions between the OH group of triazolo thiadiazole of 
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Figure 4. Human fatty acid synthase (PDB id: 2PX6).
synthesized analogues and HIS‐2481 and SER‐2308 residues (Figure 6). These interactions 
revealed the important binding mode, since these two residues are present in the “cata‐
lytic triad” of FAS‐TE domain [30]. Further, the long alkyl/alkenyl chain of our synthesized 
analogues fits into the hydrophobic groove of the substrate‐binding site. The docking pose 
and hydrogen‐bonding interactions of one of the representative compounds are shown in 
Figures 5 and 6, respectively.
Figure 5. Docking pose.
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Babak Oskouian and co‐workers reported the overexpression of fatty acid synthase in SKBR3 breast cancer cell line and. The objective of this study was to use a breast cancer‐derived cell 
line, SKBR3, as a model to define the underlying mechanism for overexpression of FAS in cancer cells [31]. Silva et al. reported a clinic pathological study of ErbB2 and Ki‐67 in head and neck squamous cell carcinoma (SCC) and the overexpression of fatty acid synthase enzyme. 
They showed FAS expression in HNSCC and pointed out ki‐67 as a useful prognostic marker 
for these tumours [32]. Michelle Agostini et al. reported the proliferation of human oral squa‐
mous carcinoma cells and fatty acid synthase. FAS is overexpressed in several human cancers, 
such as prostate, breast, bladder, liver, lung, melanoma and oral squamous cell carcinoma [33].
7. Concluding remarks
As part of a conclusion to our discussion, the various studies have shown that fatty acids not 
only augment the tumouricidal action of anticancer drugs but also enhance the uptake of anti‐
cancer drugs leading to an increase in the intracellular concentration of the anticancer drugs. 
The omega‐3 fatty acids have become adjutants to chemotherapeutic agents. Although the 
production of the above‐said fatty acids is a big challenge, a possibility would be gradually 
implementing the production of these fatty acids in clinical use. Such novel uses of fatty acids 
in cancer therapy would provide the lipid field with a new avenue to impact public health.
Author details
Jubie Selvaraj
Address all correspondence to: jubiejawahar@gmail.com
Department of Pharmaceutical Chemistry, JSS College of Pharmacy (A Constituent Institution 
of JSS University‐Mysuru), Rock Lands, Udhagamandalam, Tamil Nadu, India
Figure 6. Hydrogen‐bonding interactions.
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